Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 1 , Pages 63-80 , March 2008

Haemoglobin, oxygen carriers and perioperative organ perfusion

  • Roman Kocian, MD (Senior staff member)
    • ,
  • Donat R. Spahn, MD, FRCA (Professor and Chairman)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +41 44 255 26 95; Fax: +41 44 255 44 09.

References 

  1. Morisaki H, Sibbald WJ. Tissue oxygen delivery and the microcirculation. Critical Care Clinics. 2004;20(2):213–223
  2. Jamnicki M, Kocian R, van der Linden P, et al. Acute normovolemic hemodilution: physiology, limitations, and clinical use. Journal of Cardiothoracic and Vascular Anesthesia. 2003;17(6):747–754
  3. Spahn DR, Leone BJ, Reves JG, Pasch T. Cardiovascular and coronary physiology of acute isovolemic hemodilution: a review of nonoxygen-carrying and oxygen-carrying solutions. Anesthesia and Analgesia. 1994;78(5):1000–1021
  4. Weiskopf RB, Feiner J, Hopf H, et al. Heart rate increases linearly in response to acute isovolemic anemia. Transfusion. 2003;43(2):235–240
  5. Nozaki J, Kitahata H, Tanaka K, et al. The effects of acute normovolemic hemodilution on left ventricular systolic and diastolic function in the absence or presence of beta-adrenergic blockade in dogs. Anesthesia and Analgesia. 2002;94(5):1120–1126table of contents
  6. Hemmer M. Regional blood flow and hemorrhage. How far do the protective mechanisms go?. Intensive Care Medicine. 1996;22(10):1006–1008
  7. Hébert PC, Van der Linden P, Biro G, Hu LQ. Physiologic aspects of anemia. Critical Care Clinics. 2004;20(2):187–212
  8. Borst MM, Leschke M, Konig U, Worth H. Repetitive hemodilution in chronic obstructive pulmonary disease and pulmonary hypertension: effects on pulmonary hemodynamics, gas exchange, and exercise capacity. Respiration. 1999;66(3):225–232
  9. Deem S, Hedges RG, McKinney S, et al. Mechanisms of improvement in pulmonary gas exchange during isovolemic hemodilution. Journal of Applied Physiology. 1999;87(1):132–141
  10. Spahn DR, Schmid ER, Seifert B, Pasch T. Hemodilution tolerance in patients with coronary artery disease who are receiving chronic beta-adrenergic blocker therapy. Anesthesia and Analgesia. 1996;82(4):687–694
  11. Spahn DR, Zollinger A, Schlumpf RB, et al. Hemodilution tolerance in elderly patients without known cardiac disease. Anesthesia and Analgesia. 1996;82(4):681–686
  12. Viele MK, Weiskopf RB. What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses. Transfusion. 1994;34(5):396–401
  13. Weiskopf RB, Viele MK, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. Journal of the American Medical Association. 1998;279(3):217–221
  14. Zollinger A, Hager P, Singer T, et al. Extreme hemodilution due to massive blood loss in tumor surgery. Anesthesiology. 1997;87(4):985–987
  15. DeFoe GR, Ross CS, Olmstead EM, et al. Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Annals of Thoracic Surgery. 2001;71(3):769–776
  16. Fang WC, Helm RE, Krieger KH, et al. Impact of minimum hematocrit during cardiopulmonary bypass on mortality in patients undergoing coronary artery surgery. Circulation. 1997;96(9 Suppl):II-194–II-199
  17. Licker M, Ellenberger C, Sierra J, et al. Cardiovascular response to acute normovolemic hemodilution in patients with coronary artery diseases: assessment with transesophageal echocardiography. Critical Care Medicine. 2005;33(3):591–597
  18. Licker M, Ellenberger C, Sierra J, et al. Cardioprotective effects of acute normovolemic hemodilution in patients undergoing coronary artery bypass surgery. Chest. 2005;128(2):838–847
  19. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. The Journal of the American Medical Association. 2004;292(13):1555–1562
  20. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. New England Journal of Medicine. 1999;340(6):409–417
  21. Hébert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases?. Critical Care Medicine. 2001;29(2):227–234
  22. Spahn DR, Dettori N, Kocian R, Chassot PG. Transfusion in the cardiac patient. Critical Care Clinics. 2004;20(2):269–279
  23. Spahn DR, Seifert B, Pasch T, Schmid ER. Haemodilution tolerance in patients with mitral regurgitation. Anaesthesia. 1998;53(1):20–24
  24. Licker M, Ellenberger C, Murith N, et al. Cardiovascular response to acute normovolaemic haemodilution in patients with severe aortic stenosis: assessment with transoesophageal echocardiography. Anaesthesia. 2004;59(12):1170–1177
  25. Licker M, Sierra J, Kalangos A, et al. Cardioprotective effects of acute normovolemic hemodilution in patients with severe aortic stenosis undergoing valve replacement. Transfusion. 2007;47(2):341–350
  26. Weiskopf RB, Feiner J, Hopf HW, et al. Oxygen reverses deficits of cognitive function and memory and increased heart rate induced by acute severe isovolemic anemia. Anesthesiology. 2002;96(4):871–877
  27. Weiskopf RB, Kramer JH, Viele M, et al. Acute severe isovolemic anemia impairs cognitive function and memory in humans. Anesthesiology. 2000;92(6):1646–1652
  28. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004;363(9407):417–421
  29. Houston F, Foster JD, Chong A, et al. Transmission of BSE by blood transfusion in sheep. Lancet. 2000;356(9234):999–1000
  30. Hunter N, Foster J, Chong A, et al. Transmission of prion diseases by blood transfusion. Journal of General Virology. 2002;83(Pt 11):2897–2905
  31. Aguzzi A, Glatzel M. vCJD tissue distribution and transmission by transfusion – a worst-case scenario coming true?. Lancet. 2004;363(9407):411–412
  32. Kopko PM, Holland PV. Transfusion-related acute lung injury. British Journal of Haematology. 1999;105(2):322–329
  33. Wallis JP. Transfusion-related acute lung injury (TRALI) – under-diagnosed and under-reported. British Journal of Anaesthesia. 2003;90(5):573–576
  34. Rana R, Fernández-Pérez ER, Khan SA, et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion. 2006;46(9):1478–1483
  35. Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. Critical Care Medicine. 2005;33(4):721–726
  36. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood. 2005;105(6):2266–2273
  37. Blumberg N, Heal JM. Blood transfusion immunomodulation: the silent epidemic. Archives of Pathology and Laboratory Medicine. 1998;122(2):117–119
  38. Vamvakas EC. Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials. Transfusion. 1996;36(2):175–186
  39. Klein HG. Immunomodulatory aspects of transfusion: a once and future risk?. Anesthesiology. 1999;91(3):861–865
  40. Amato AC, Pescatori M. Effect of perioperative blood transfusions on recurrence of colorectal cancer: meta-analysis stratified on risk factors. Diseases of the Colon and Rectum. 1998;41(5):570–585
  41. Taylor RW, O'Brien J, Trottier SJ, et al. Red blood cell transfusions and nosocomial infections in critically ill patients. Critical Care Medicine. 2006;34(9):2302–2308quiz 2309
  42. Spahn DR, Madjdpour C. Physiologic transfusion triggers: do we have to use (our) brain?. Anesthesiology. 2006;104(5):905–906
  43. Spahn DR, Smith LR, Veronee CD, et al. Acute isovolemic hemodilution and blood transfusion. Effects on regional function and metabolism in myocardium with compromised coronary blood flow. Journal of Thoracic and Cardiovascular Surgery. 1993;105(4):694–704
  44. Leung JM, Weiskopf RB, Feiner J, et al. Electrocardiographic ST-segment changes during acute, severe isovolemic hemodilution in humans. Anesthesiology. 2000;93(4):1004–1010
  45. Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion. 2002;42(7):812–818
  46. American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies . Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology. 2006;105(1):198–208
  47. Simon TL, Alverson DC, AuBuchon J, et al. Practice parameter for the use of red blood cell transfusions: developed by the Red Blood Cell Administration Practice Guideline Development Task Force of the College of American Pathologists. Archives of Pathology and Laboratory Medicine. 1998;122(2):130–138
  48. Arifin DR, Palmer AF. Polymersome encapsulated hemoglobin: a novel type of oxygen carrier. Biomacromolecules. 2005;6(4):2172–2181
  49. Spahn DR, Kocian R. The place of artificial oxygen carriers in reducing allogeneic blood transfusions and augmenting tissue oxygenation. Canadian Journal of Anaesthesia. 2003;50(6 Suppl):S41–S47
  50. Spahn DR, Kocian R. Artificial O2 carriers: status in 2005. Current Pharmaceutical Design. 2005;11(31):4099–4114
  51. Winslow RM. Current status of oxygen carriers (‘blood substitutes’): 2006. Vox Sanguinis. 2006;91(2):102–110
  52. Spahn DR, Pasch T. Physiological properties of blood substitutes. News in Physiological Sciences. 2001;16:38–41
  53. Winslow RM. Blood substitutes. Advanced Drug Delivery Reviews. 2000;40(3):131–142
  54. Stowell CP, Levin J, Spiess BD, et al. Progress in the development of RBC substitutes. Transfusion. 2001;41(2):287–299
  55. Kasper SM, Walter M, Grune F, et al. Effects of a hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesthesia and Analgesia. 1996;83(5):921–927
  56. Dietz NM, Martin CM, Beltran-del-Rio AG, Joyner MJ. The effects of cross-linked hemoglobin on regional vascular conductance in dogs. Anesthesia and Analgesia. 1997;85(2):265–273
  57. Schechter AN, Gladwin MT. Hemoglobin and the paracrine and endocrine functions of nitric oxide. New England Journal of Medicine. 2003;348(15):1483–1485
  58. Gulati A, Sharma AC, Singh G. Role of endothelin in the cardiovascular effects of diaspirin crosslinked and stroma reduced hemoglobin. Critical Care Medicine. 1996;24(1):137–147
  59. Gulati A, Rebello S. Role of adrenergic mechanisms in the pressor effect of diaspirin cross-linked hemoglobin. Journal of Laboratory and Clinical Medicine. 1994;124(1):125–133
  60. Cabrales P, Tsai AG, Winslow RM, Intaglietta M. Effects of extreme hemodilution with hemoglobin-based O2 carriers on microvascular pressure. American Journal of Physiology. Heart and Circulatory Physiology. 2005;288(5):H2146–H2153
  61. Rohlfs RJ, Bruner E, Chiu A, et al. Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide. Journal of Biological Chemistry. 1998;273(20):12128–12134
  62. Migita R, Gonzales A, Gonzales ML, et al. Blood volume and cardiac index in rats after exchange transfusion with hemoglobin-based oxygen carriers. Journal of Applied Physiology. 1997;82(6):1995–2002
  63. Habler OP, Kleen MS, Hutter JW, et al. Effects of hyperoxic ventilation on hemodilution-induced changes in anesthetized dogs. Transfusion. 1998;38(2):135–144
  64. Kemming GI, Meisner FG, Kleen M, et al. Hyperoxic ventilation at the critical haematocrit. Resuscitation. 2003;56(3):289–297
  65. van Bommel J, Trouwborst A, Schwarte L, et al. Intestinal and cerebral oxygenation during severe isovolemic hemodilution and subsequent hyperoxic ventilation in a pig model. Anesthesiology. 2002;97(3):660–670
  66. Kleen M, Habler O, Hutter J, et al. Normovolaemic haemodilution and hyperoxia have no effect on fractal dimension of regional myocardial perfusion in dogs. Acta Physiologica Scandinavica. 1998;162(4):439–446
  67. Tsai AG, Cabrales P, Winslow RM, Intaglietta M. Microvascular oxygen distribution in awake hamster window chamber model during hyperoxia. American Journal of Physiology. Heart and Circulatory Physiology. 2003;285(4):H1537–H1545
  68. Meier J, Kemming GI, Kisch-Wedel H, et al. Hyperoxic ventilation reduces 6-hour mortality at the critical hemoglobin concentration. Anesthesiology. 2004;100(1):70–76
  69. Zimmerman JJ. Deciphering the dark side of free hemoglobin in sepsis. Critical Care Medicine. 1999;27(4):685–686
  70. Doherty CP, Weaver LT, Prentice AM. Micronutrient supplementation and infection: a double-edged sword?. Journal of Pediatric Gastroenterology and Nutrition. 2002;34(4):346–352
  71. Javadi P, Bucman TG, Stromberg PE, et al. High-dose exogenous iron following cecal ligation and puncture increases mortality rate in mice and is associated with an increase in gut epithelial and splenic apoptosis. Critical Care Medicine. 2004;32(5):1178–1185
  72. Ma Z, Monk TG, Goodnough LT, et al. Effect of hemoglobin- and Perflubron-based oxygen carriers on common clinical laboratory tests. Clinical Chemistry. 1997;43(9):1732–1737
  73. Reppucci AJ, Mattia-Goldberg C, Przybelski RJ, et al. The effects of diaspirin-crosslinked hemoglobin on the assessment of immunohematology profiles. Transfusion. 1997;37(11–12):1143–1148
  74. Winslow RM. Red cell substitutes. Seminars in Hematology. 2007;44(1):51–59
  75. Brandt JL, Frank NR, Lichtman HC. The effects of hemoglobin solutions on renal functions in man. Blood. 1951;6(11):1152–1158
  76. Miller JH, McDonald RK. The effect of hemoglobin on renal function in the human. Journal of Clinical Investigation. 1951;30(10):1033–1040
  77. Savitsky JP, Doczi J, Black J, Arnold JD. A clinical safety trial of stroma-free hemoglobin. Clinical Pharmacology and Therapeutics. 1978;23(1):73–80
  78. Rosen AL, Gould SA, Sehgal LR, et al. Effect of hemoglobin solution on compensation to anemia in the erythrocyte-free primate. Journal of Applied Physiology. 1990;68(3):938–943
  79. Jahr JS, Varma N. PolyHeme. Northfield Laboratories. IDrugs. 2004;7(5):478–482
  80. Gould SA, Moore EE, Moore FA, et al. Clinical utility of human polymerized hemoglobin as a blood substitute after acute trauma and urgent surgery. Journal of Trauma. 1997;43(2):325–331discussion 331–332
  81. Gould SA, Moore EE, Hoyt DB, et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. Journal of the American College of Surgeons. 1998;187(2):113–120discussion 120–122
  82. Gould SA, Moore EE, Hoyt DB, et al. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. Journal of the American College of Surgeons. 2002;195(4):452–455445–452; discussion
  83. Kasper SM, Grune F, Walter M, et al. The effects of increased doses of bovine hemoglobin on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesthesia and Analgesia. 1998;87(2):284–291
  84. Levy JH, Goodnough LT, Greilich PE, et al. Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. Journal of Thoracic and Cardiovascular Surgery. 2002;124(1):35–42
  85. LaMuraglia GM, O'Hara PJ, Baker WH, et al. The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution. Journal of Vascular Surgery. 2000;31(2):299–308
  86. Sprung J, Kindscher JD, Wahr JA, et al. The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: results of a multicenter, randomized, single-blinded trial. Anesthesia and Analgesia. 2002;94(4):799–808table of contents
  87. Kerger H, Tsa AG, Saltzman DJ, et al. Fluid resuscitation with O2 vs. non-O2 carriers after 2h of hemorrhagic shock in conscious hamsters. American Journal of Physiology. 1997;272(1 Pt 2):H525–H537
  88. Cheng DC, Mazer CD, Martineau R, et al. A phase II dose-response study of hemoglobin raffimer (Hemolink) in elective coronary artery bypass surgery. Journal of Thoracic and Cardiovascular Surgery. 2004;127(1):79–86
  89. Hill SE, Gottschalk LI, Grichnik K. Safety and preliminary efficacy of hemoglobin raffimer for patients undergoing coronary artery bypass surgery. Journal of Cardiothoracic and Vascular Anesthesia. 2002;16(6):695–702
  90. Greenburg AG, Kim HW. Use of an oxygen therapeutic as an adjunct to intraoperative autologous donation to reduce transfusion requirements in patients undergoing coronary artery bypass graft surgery. Journal of the American College of Surgeons. 2004;198(3):373–383discussion 384–385
  91. Chatterjee R, Welty EV, Walder RY, et al. Isolation and characterization of a new hemoglobin derivative cross-linked between the alpha chains (lysine 99 alpha 1–--lysine 99 alpha 2). Journal of Biological Chemistry. 1986;261(21):9929–9937
  92. Vandegriff KD, Medina F, Marini MA, Winslow RM. Equilibrium oxygen binding to human hemoglobin cross-linked between the alpha chains by bis (3,5-dibromosalicyl) fumarate. Journal of Biological Chemistry. 1989;264(30):17824–17833
  93. Xu L, Sun L, Rollwagen FM, et al. Cellular responses to surgical trauma, hemorrhage, and resuscitation with diaspirin cross-linked hemoglobin in rats. Journal of Trauma. 1997;42(1):32–41
  94. Meisner FG, Kemming GI, Habler OP, et al. Diaspirin crosslinked hemoglobin enables extreme hemodilution beyond the critical hematocrit. Critical Care Medicine. 2001;29(4):829–838
  95. Lamy ML, Daily EK, Brichant JF, et al. Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. The DCLHb Cardiac Surgery Trial Collaborative Group. Anesthesiology. 2000;92(3):646–656
  96. Schubert A, Przybelski RJ, Eidt JF, et al. Diaspirin-crosslinked hemoglobin reduces blood transfusion in noncardiac surgery: a multicenter, randomized, controlled, double-blinded trial. Anesthesia and Analgesia. 2003;97(2):323–332table of contents
  97. Sloan EP, Koenigsberg M, Gens D, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. The Journal of the American Medical Association. 1999;282(19):1857–1864
  98. Kerner T, Ahlers O, Veit S, et al. DCL-Hb for trauma patients with severe hemorrhagic shock: the European “On-Scene” multicenter study. Intensive Care Medicine. 2003;29(3):378–385
  99. Hoffman SJ, Looker DL, Roehrich JM, et al. Expression of fully functional tetrameric human hemoglobin in Escherichia coli. Procedings of the National Academy of Sciences of the United States of America. 1990;87(21):8521–8525
  100. Looker D, Abbott-Brown D, Cozart P, et al. A human recombinant haemoglobin designed for use as a blood substitute. Nature. 1992;356(6366):258–260
  101. Siegel JH, Fabian M, Smith JA, Costantino D. Use of recombinant hemoglobin solution in reversing lethal hemorrhagic hypovolemic oxygen debt shock. Journal of Trauma. 1997;42(2):199–212
  102. Olson JS, Foley EW, Rogge C, et al. No scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free Radical Biology and Medicine. 2004;36(6):685–697
  103. Doherty DH, Doyle MP, Curry SR, et al. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nature Biotechnology. 1998;16(7):672–676
  104. Loeb AL, McIntosh LJ, Raj NR, Longnecker DE. Resuscitation after hemorrhage using recombinant human hemoglobin (rHb1.1) in rats: effects on nitric oxide and prostanoid systems. Critical Care Medicine. 1998;26(6):1071–1080
  105. Sillerud LO, Caprihan A, Berton N, Rosenthal GJ. Efficacy of recombinant human Hb by 31P-NMR during isovolemic total exchange transfusion. Journal of Applied Physiology. 1999;86(3):887–894
  106. Razack S, D'Agnillo F, Chang TM. Crosslinked hemoglobin-superoxide dismutase-catalase scavenges free radicals in a rat model of intestinal ischemia-reperfusion injury. Artificial Cells, Blood Substitutes, and Immobilization Biotechnology. 1997;25(1-2):181–192
  107. Powanda DD, Chang TM. Cross-linked polyhemoglobin-superoxide dismutase-catalase supplies oxygen without causing blood-brain barrier disruption or brain edema in a rat model of transient global brain ischemia-reperfusion. Artificial Cells, Blood Substitutes, and Immobilization Biotechnology. 2002;30(1):23–37
  108. McCarthy MR, Vandegriff KD, Winslow RM. The role of facilitated diffusion in oxygen transport by cell-free hemoglobins: implications for the design of hemoglobin-based oxygen carriers. Biophysical Chemistry. 2001;92(1-2):103–117
  109. Vandegriff KD, Malavalli A, Wooldridge J, et al. MP4, a new nonvasoactive PEG-Hb conjugate. Transfusion. 2003;43(4):509–516
  110. Sakai H, Hara H, Yuasa M, et al. Molecular dimensions of Hb-based O(2) carriers determine constriction of resistance arteries and hypertension. American Journal of Physiology. Heart and Circulatory Physiology. 2000;279(3):H908–H915
  111. Intaglietta M, Johnson PC, Winslow RM. Microvascular and tissue oxygen distribution. Cardiovascular Research. 1996;32(4):632–643
  112. Winslow RM, Vandegriff K, Wettstein R, et al. Autoregulation and vasoconstriction: foundation for a new generation of blood substitutes. Blood. 2002;100:210;[abstract]
  113. Tsai AG, Cabrales P, Manjula BN, et al. Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers. Blood. 2006;108(10):3603–3610
  114. Tsai AG, Vandegriff KD, Intaglietta M, Winslow RM. Targeted O2 delivery by low-P50 hemoglobin: a new basis for O2 therapeutics. American Journal of Physiology. Heart and Circulatory Physiology. 2003;285(4):H1411–H1419
  115. Wettstein R, Tsai AG, Erni D, et al. Resuscitation with polyethylene glycol-modified human hemoglobin improves microcirculatory blood flow and tissue oxygenation after hemorrhagic shock in awake hamsters. Critical Care Medicine. 2003;31(6):1824–1830
  116. Drobin D, Kjellstrom BT, Malm E, et al. Hemodynamic response and oxygen transport in pigs resuscitated with maleimide-polyethylene glycol-modified hemoglobin (MP4). Journal of Applied Physiology. 2004;96(5):1843–1853
  117. Winslow RM, Lohman J, Malavalli A, Vandegriff KD. Comparison of PEG-modified albumin and hemoglobin in extreme hemodilution in the rat. Journal of Applied Physiology. 2004;97(4):1527–1534
  118. Bjorkholm M, Fagrell B, Przybelski R, et al. A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol. Haematologica. 2005;90(4):505–515
  119. Olofsson C, Ahl T, Johansson T, et al. A multicenter clinical study of the safety and activity of maleimide-polyethylene glycol-modified Hemoglobin (Hemospan) in patients undergoing major orthopedic surgery. Anesthesiology. 2006;105(6):1153–1163
  120. Matheson B, Razynska A, Kwansa H, Bucci E. Appearance of dissociable and cross-linked hemoglobins in the renal hilar lymph. Journal of Laboratory and Clinical Medicine. 2000;135(6):459–464
  121. Nemoto M, Mito T, Brinigar WS, et al. Salvage of focal cerebral ischemic damage by transfusion of high O2-affinity recombinant hemoglobin polymers in mouse. Journal of Applied Physiology. 2006;100(5):1688–1691
  122. Riess JG. Overview of progress in the fluorocarbon approach to in vivo oxygen delivery. Biomaterials, Artificial Cells, and Immobilization Biotechnology. 1992;20(2–4):183–202
  123. Riess JG. Oxygen carriers (“blood substitutes”) – raison d'etre, chemistry, and some physiology. Chemical Reviews. 2001;101(9):2797–2920
  124. Cleman M, Jaffee CC, Wohlgelernter D. Prevention of ischemia during percutaneous transluminal coronary angioplasty by transcatheter infusion of oxygenated Fluosol DA 20%. Circulation. 1986;74(3):555–562
  125. Young LH, Jaffe CC, Revkin JH, et al. Metabolic and functional effects of perfluorocarbon distal perfusion during coronary angioplasty. American Journal of Cardiology. 1990;65(15):986–990
  126. Kent KM, Cleman MW, Cowley MJ, et al. Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol. American Journal of Cardiology. 1990;66(3):279–284
  127. Bajaj AK, Cobb MA, Virmani R, et al. Limitation of myocardial reperfusion injury by intravenous perfluorochemicals. Role of neutrophil activation. Circulation. 1989;79(3):645–656
  128. Forman MB, Perry JM, Wilson BH, et al. Demonstration of myocardial reperfusion injury in humans: results of a pilot study utilizing acute coronary angioplasty with perfluorochemical in anterior myocardial infarction. Journal of the American College of Cardiology. 1991;18(4):911–918
  129. Spence RK, McCoy S, Costabile J, et al. Fluosol DA-20 in the treatment of severe anemia: randomized, controlled study of 46 patients. Critical Care Medicine. 1990;18(11):1227–1230
  130. Gould SA, Rosen AL, Sehgal LR, et al. Fluosol-DA as a red-cell substitute in acute anemia. New England Journal of Medicine. 1986;314(26):1653–1656
  131. Wahr JA, Trouwborst A, Spence RK, et al. A pilot study of the effects of a perflubron emulsion, AF 0104, on mixed venous oxygen tension in anesthetized surgical patients. Anesthesia and Analgesia. 1996;82(1):103–107
  132. Leese PT, Noveck RJ, Shorr JS, et al. Randomized safety studies of intravenous perflubron emulsion. I. Effects on coagulation function in healthy volunteers. Anesthesia and Analgesia. 2000;91(4):804–811
  133. Keipert PE, Faithfull NS, Bradley JD, et al. Oxygen delivery augmentation by low-dose perfluorochemical emulsion during profound normovolemic hemodilution. Advances in Experimental Medicine and Biology. 1994;345:197–204
  134. Holman WL, Spruell RD, Ferguson ER, et al. Tissue oxygenation with graded dissolved oxygen delivery during cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery. 1995;110(3):774–785
  135. Spahn DR, van Brempt R, Theilmeier G, et al. Perflubron emulsion delays blood transfusions in orthopedic surgery. European Perflubron Emulsion Study Group. Anesthesiology. 1999;91(5):1195–1208
  136. Noveck RJ, Shannon EJ, Leese PT, et al. Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers. Anesthesia and Analgesia. 2000;91(4):812–822
  137. Spahn DR, Waschke KF, Standl T, et al. Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery: results of a European phase 3 study. Anesthesiology. 2002;97(6):1338–1349
  138. Sakai H, Hamada K, Takeoka S, et al. Physical properties of hemoglobin vesicles as red cell substitutes. Biotechnology Progress. 1996;12(1):119–125
  139. Phillips WT, Klipper RW, Awasthi VD, et al. Polyethylene glycol-modified liposome-encapsulated hemoglobin: a long circulating red cell substitute. Journal of Pharmacology and Experimental Theraputics. 1999;288(2):665–670
  140. Chang TM. Future generations of red blood cell substitutes. Journal of Internal Medicine. 2003;253(5):527–535
  141. Pagel PS, Hettrick DA, Montgomery MW, et al. RSR13, a synthetic modifier of hemoglobin-oxygen affinity, enhances the recovery of stunned myocardium in anesthetized dogs. Journal of Pharmacology and Experimental Theraputics. 1998;285(1):1–8
  142. Wahr JA, Gerber M, Venitz J, Baliga N. Allosteric modification of oxygen delivery by hemoglobin. Anesthesia and Analgesia. 2001;92(3):615–620
  143. Eichelbrönner O, D'Almeida M, Sielenkämper A, et al. Increasing P(50) does not improve DO(2CRIT) or systemic VO(2) in severe anemia. American Journal of Physiology. Heart and Circulatory Physiology. 2002;283(1):H92–H101

PII: S1521-6896(07)00091-2

doi: 10.1016/j.bpa.2007.10.003

Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 1 , Pages 63-80 , March 2008

Article Tools